Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Posting of Circular and Notice of General Meeting

8th Jul 2025 07:00

RNS Number : 0671Q
Aptamer Group PLC
08 July 2025
 

 

8 July 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Posting of Circular and Notice of General Meeting

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces further to the announcement on 4 July 2025 relating to its proposed placing to raise £2.0 million (before expenses) ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders.

 

The Directors confirm they are to convene a General Meeting of the Company at 11.00 am on Thursday, 24 July 2025, at Windmill House, Innovation Way, York, YO10 5BR.

 

The Circular and Notice of General Meeting is available on the Company's website at https://aptamergroup.com/investors/reports-and-presentations.

 

The results of voting on all resolutions at the General Meeting will be announced via the Regulatory News Service, and the full results of the voting will be published on the Company's website as soon as practicable after the conclusion of the General Meeting.

 

- Ends -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley

 

 

+44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Jade Bayat

 

 

+44 (0) 20 3368 3550

Turner Pope Investments (TPI) Limited - Broker

James Pope / Andrew Thacker

 

 

+44 (0) 20 3657 0050

Northstar Communication Limited

Sarah Hollins

+44 (0) 113 730 3896

 

About Aptamer Group plc

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGBRGDRLGGDGUR

Related Shares:

Aptamer Group
FTSE 100 Latest
Value8,941.12
Change-34.54